公开(公告)号：US20160347724A1

公开(公告)日：2016-12-01

申请号：US15117539

申请日：2015-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zenichi IKEDA ,  Minoru SASAKI ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Yoichi NISHIKAWA

IPC: C07D261/04 ,  C07D413/10

CPC classification number: C07D261/04 ,  C07D413/10

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US20180072694A1

公开(公告)日：2018-03-15

申请号：US15561613

申请日：2016-03-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Keiko Kakegawa ,  Zenichi IKEDA ,  Minoru SASAKI ,  Fumiaki KIKUCHI ,  Yoichi NISHIKAWA

IPC: C07D307/79 ,  C07D413/04 ,  C07F9/655

CPC classification number: C07D307/79 ,  A61K31/343 ,  A61K31/422 ,  A61K31/665 ,  A61P3/04 ,  A61P3/10 ,  C07D413/04 ,  C07F9/38 ,  C07F9/65517

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].

公开(公告)号：US20160355494A1

公开(公告)日：2016-12-08

申请号：US15117538

申请日：2015-02-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Minoru SASAKI ,  Keiko KAKEGAWA ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Yoichi NISHIKAWA

IPC: C07D307/81

CPC classification number: C07D307/81

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US20170349605A1

公开(公告)日：2017-12-07

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru SASAKI ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Keiko KAKEGAWA ,  Yoichi NISHIKAWA ,  Shigekazu SASAKI ,  Koichiro FUKUDA ,  Kazuaki TAKAMI ,  Yoshihiro BANNO ,  Masahiro KAMAURA

IPC: C07D495/04 ,  C07D491/044 ,  C07D413/06 ,  C07D323/00 ,  C07D313/00 ,  C07D321/12 ,  C07D321/00 ,  C07D313/20 ,  C07D493/04 ,  C07D405/06

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].